{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T10:30:12Z","timestamp":1793356212984,"version":"4.5.0"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejog.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Obstetrics & Gynecology and Reproductive Biology"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1016\/j.ejogrb.2016.11.013","type":"journal-article","created":{"date-parts":[[2016,11,16]],"date-time":"2016-11-16T20:00:04Z","timestamp":1479326404000},"page":"13-21","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["A comparative systematic review of Yasmin (drospirenone pill) versus standard treatment options for symptoms of polycystic ovary syndrome"],"prefix":"10.1016","volume":"210","author":[{"given":"Jing","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxia","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejogrb.2016.11.013_bib0005","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1056\/NEJMra041536","article-title":"Polycystic ovary syndrome","volume":"352","author":"Ehrmann","year":"2005","journal-title":"New Engl J Med"},{"key":"10.1016\/j.ejogrb.2016.11.013_bib0010","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/S0140-6736(99)00218-4","article-title":"The pathogenesis of polycystic ovary syndrome: the enigma unravels","volume":"354","author":"Balen","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.ejogrb.2016.11.013_bib0015","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1093\/humupd\/dmi005","article-title":"Combined oral contraceptives in the treatment of polycystic ovary syndrome","volume":"11","author":"Vrbikova","year":"2005","journal-title":"Hum Reprod Update"},{"issue":"Suppl 3","key":"10.1016\/j.ejogrb.2016.11.013_bib0020","first-page":"19","article-title":"Antimineralocorticoid activity of a novel oral contraceptive containing drospirenone, a unique progestogen resembling natural progesterone","volume":"7","author":"Oelkers","year":"2002","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"10.1016\/j.ejogrb.2016.11.013_bib0025","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1080\/ejc.8.1.37.51","article-title":"Effect of an oral contraceptive containing drospirenone and ethinylestradiol on general well-being and fluid-related symptoms","volume":"8","author":"Apter","year":"2003","journal-title":"Eur J Contracept Reprod Health Care"},{"issue":"Suppl 3","key":"10.1016\/j.ejogrb.2016.11.013_bib0030","first-page":"35","article-title":"Experiences with Yasmin: the acceptability of a novel oral contraceptive and its effect on well-being","volume":"7","author":"Mansour","year":"2002","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"10.1016\/j.ejogrb.2016.11.013_bib0035","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1016\/j.fertnstert.2009.10.016","article-title":"Comparison of effects of 3mg drospirenone plus 20mg ethinyl estradiol alone or combined with metformin or cyproterone acetate on classic metabolic cardiovascular risk factors in nonobese women with polycystic ovary syndrome","volume":"94","author":"Fruzzetti","year":"2010","journal-title":"Fertil Steril"},{"key":"10.1016\/j.ejogrb.2016.11.013_bib0040","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.contraception.2010.02.009","article-title":"Effect of oral contraceptive containing ethinyl estradiol combined with drospirenone vs: desogestrel on clinical and biochemical parameters in patients with polycystic ovary syndrome","volume":"82","author":"Kriplani","year":"2010","journal-title":"Contraception"},{"key":"10.1016\/j.ejogrb.2016.11.013_bib0045","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.contraception.2010.04.002","article-title":"Effect of oral contraceptives on markers of hyperandrogenism and SHBG in women with polycystic ovary syndrome","volume":"82","author":"De Leo","year":"2010","journal-title":"Contraception"},{"key":"10.1016\/j.ejogrb.2016.11.013_bib0050","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.fertnstert.2012.06.035","article-title":"Comparative study of the therapeutic effects of oral contraceptive pills containing desogestrel, cyproterone acetate, and drospirenone in patients with polycystic ovary syndrome","volume":"98","author":"Bhattacharya","year":"2012","journal-title":"Fertil Steril"},{"key":"10.1016\/j.ejogrb.2016.11.013_bib0055","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s00404-013-2742-y","article-title":"The effects of drospirenone-ethinyl estradiol and drospirenoneethinyl estradiol+metformin on ovarian ultrasonographic markers, body fat mass index, leptin, and ghrelin","volume":"288","author":"Cakiroglu","year":"2013","journal-title":"Arch Gynecol Obstet"},{"key":"10.1016\/j.ejogrb.2016.11.013_bib0060","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1111\/j.1365-2265.2012.04436.x","article-title":"The effects of treatment with drospirenone\/ethinyl oestradiol alone or in combination with metformin on elastic properties of aorta in women with polycystic ovary syndrome","volume":"77","author":"Kaya","year":"2012","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.ejogrb.2016.11.013_bib0065","doi-asserted-by":"crossref","first-page":"587","DOI":"10.3109\/09513590.2010.507283","article-title":"The impact of oral contraceptives and metformin on anti-mullerian hormone serum levels in women with polycystic ovary syndrome and biochemical hyperandrogenemia","volume":"27","author":"Panidis","year":"2011","journal-title":"Gynecol Endocrinol"},{"key":"10.1016\/j.ejogrb.2016.11.013_bib0070","doi-asserted-by":"crossref","first-page":"488","DOI":"10.14310\/horm.2002.1553","article-title":"The benefit-to-risk ratio of common treatments in PCOS: effect of oral contraceptives versus metformin on atherogenic markers","volume":"13","author":"Christakou","year":"2014","journal-title":"Hormones"},{"key":"10.1016\/j.ejogrb.2016.11.013_bib0075","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1210\/jc.2003-031281","article-title":"Ethinylestradiol-drospirenone, flutamide-metformin, or both for adolescents and women with hyperinsulinemic hyperandrogenism: opposite effects on adipocytokines and body adiposity","volume":"89","author":"Ibanez","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ejogrb.2016.11.013_bib0080","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1210\/jc.2004-1405","article-title":"Flutamide-metformin plus ethinylestradiol-drospirenone for lipolysis and antiatherogenesis in young women with ovarian hyperandrogenism: the key role of metformin at the start and after more than one year of therapy","volume":"90","author":"Ibanez","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ejogrb.2016.11.013_bib0085","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1177\/1933719113488444","article-title":"Effects of drospirenone\u2013ethinylestradiol and\/or metformin on CD4\u2009+\u2009CD28null\u2009T lymphocytes frequency in women with hyperinsulinemia having polycystic ovary syndrome: a randomized clinical trial","volume":"20","author":"Moro","year":"2013","journal-title":"Reprod Sci"},{"key":"10.1016\/j.ejogrb.2016.11.013_bib0090","first-page":"6015","article-title":"The use of marvelon,daine-35 and yasmin in treating Polycystic Ovary Syndrome","volume":"35","author":"Mao","year":"2014","journal-title":"Jilin Med J"},{"key":"10.1016\/j.ejogrb.2016.11.013_bib0095","first-page":"52","article-title":"The effect of the composite tablet of droopiness ethylene lestrade in poly cystic ovary syndrome","volume":"22","author":"Huang","year":"2016","journal-title":"Hebei Med"},{"key":"10.1016\/j.ejogrb.2016.11.013_bib0100","first-page":"165","article-title":"The effect and prognostic analysis of drospirenone and ethinylestradiol tablets combined with metformin in treating Polycystic Ovary Syndrome","volume":"12","author":"Huang","year":"2015","journal-title":"J North Phar"},{"key":"10.1016\/j.ejogrb.2016.11.013_bib0105","first-page":"75","article-title":"The effect of ethinylestradiol and cyproterone acetate versus drospirenone and ethinylestradiol in treating hyperandrogenemia of Polycystic Ovary Syndrome","volume":"56","author":"Wang","year":"2016","journal-title":"Shandong Med J"},{"key":"10.1016\/j.ejogrb.2016.11.013_bib0110","first-page":"179","article-title":"Comparison of effects of yasmin versus diane-35 in treating polycystic ovary syndrome","volume":"13","author":"Huang","year":"2015","journal-title":"Contemp Med Forum"},{"key":"10.1016\/j.ejogrb.2016.11.013_bib0115","first-page":"5018","article-title":"Clinical observation on the effects of Yasmin combined with metformin and life style's intervention in treating adolescent patients with Polycystic Ovary Syndrome","volume":"13","author":"Fu","year":"2015","journal-title":"Maternal Child Health Care China"},{"key":"10.1016\/j.ejogrb.2016.11.013_bib0120","first-page":"70","article-title":"Observation on the effects of Yasmin combined with metformin in treating Polycystic Ovary Syndrome","volume":"12","author":"Li","year":"2015","journal-title":"J North Phar"},{"key":"10.1016\/j.ejogrb.2016.11.013_bib0125","first-page":"96","article-title":"Observation of adolescents with polycystic ovary syndrome treated by Yasmin combined with Metformin","volume":"23","author":"Xu","year":"2013","journal-title":"China J Mod Med"},{"key":"10.1016\/j.ejogrb.2016.11.013_bib0130","first-page":"1944","article-title":"Comparison of clinical efficacies of Yasmin and Diane-35 in treatment of polycystic ovary syndrome","volume":"27","author":"Qin","year":"2012","journal-title":"Maternal Child Health Care China"}],"container-title":["European Journal of Obstetrics & Gynecology and Reproductive Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301211516310259?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301211516310259?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T14:59:39Z","timestamp":1779807579000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301211516310259"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":26,"alternative-id":["S0301211516310259"],"URL":"https:\/\/doi.org\/10.1016\/j.ejogrb.2016.11.013","relation":{},"ISSN":["0301-2115"],"issn-type":[{"value":"0301-2115","type":"print"}],"subject":[],"published":{"date-parts":[[2017,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A comparative systematic review of Yasmin (drospirenone pill) versus standard treatment options for symptoms of polycystic ovary syndrome","name":"articletitle","label":"Article Title"},{"value":"European Journal of Obstetrics & Gynecology and Reproductive Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejogrb.2016.11.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}